Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services
News Jul 09, 2015
To be established over the next few months, the new, hand-picked Board will bring together the most highly experienced scientists with extensive drug discovery backgrounds in the fields of Chronic Pain and CNS research, extending Cellectricon’s expertise in these areas.
“Cellectricon is assembling a first-class team of scientists and engineers - all focused on the challenging task of developing enhanced assay technologies for early stage Pain and CNS drug discovery” said Dr Johnson. “I am pleased to join its Scientific Advisory Board and look forward to helping the company as it pursues this mission.”
Edwin Johnson has over 20 years’ experience in CNS discovery and development, especially in the areas of neuroscience. With over 50 peer-reviewed publications and 10 patents, he has been extensively involved in numerous drug discovery programmes. In addition, he has also headed up teams working on drugs for the treatment of cognitive disorders, Parkinson’s disease and depression, taking them through clinical development. Since 2012, Edwin has headed the Stockholm Brain Institute and is the CNS lead at Karolinska Institutet Innovations.
“In the past 12 months we have gained significant traction with our Discovery Services offering based on our proprietary Cellaxess® Elektra phenotypic assay platform and expert scientific staff”, said Cellectricon’s CEO, David Burns. “In order to further add value, we are expanding our Discovery Services offering to include a range of complementary cell-based assays that encompass profiling further along the drug discovery process. We are very pleased to welcome Dr Johnson to our newly-formed Scientific Advisory Board, as he will provide valuable domain knowledge that will aid the development of our proprietary Discovery Services for our clients.”
Small Tweak Makes Progress Towards Improved Flu TreatmentNews
Researchers report that a tweak to a small-molecule drug shows promise for future production of new antiviral therapies that could help patients, regardless of the strain with which they are infected.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018